- Moneycontrol /
- Market /
- Pharmaceuticals /
- QUARTERLY RESULTS
BSE Live
Jul 13, 11:42Prev. Close
820.75
Open Price
825.00
Bid Price (Qty.)
812.50 (195)
Offer Price (Qty.)
812.80 (74)
NSE Live
Jul 13, 11:42Prev. Close
820.75
Open Price
827.10
Bid Price (Qty.)
812.75 (113)
Offer Price (Qty.)
812.85 (42)
| Quarterly Results of Aurobindo Pharma (in Rs. Cr.) | Mar '20 | Dec '19 | Sep '19 | Jun '19 | Mar '19 | |
| Net Sales/Income from operations | 3,534.28 | 3,258.10 | 3,145.12 | 2,997.03 | 3,196.20 | |
| Other Operating Income | 86.04 | 87.57 | 76.54 | 81.80 | 84.38 | |
| Total Income From Operations | 3,620.32 | 3,345.67 | 3,221.66 | 3,078.83 | 3,280.58 | |
| EXPENDITURE | ||||||
| Consumption of Raw Materials | 1,792.76 | 1,753.23 | 1,586.16 | 1,615.40 | 1,708.20 | |
| Purchase of Traded Goods | 0.68 | 1.11 | 1.34 | 2.38 | 0.58 | |
| Increase/Decrease in Stocks | -126.92 | -64.90 | 38.01 | -75.72 | -136.90 | |
| Power & Fuel | -- | -- | -- | -- | -- | |
| Employees Cost | 424.94 | 384.91 | 374.06 | 377.56 | 361.82 | |
| depreciat | 118.85 | 118.55 | 117.93 | 115.15 | 109.33 | |
| Excise Duty | -- | -- | -- | -- | -- | |
| Admin. And Selling Expenses | -- | -- | -- | -- | -- | |
| R & D Expenses | -- | -- | -- | -- | -- | |
| Provisions And Contingencies | -- | -- | -- | -- | -- | |
| Exp. Capitalised | -- | -- | -- | -- | -- | |
| Other Expenses | 680.27 | 620.14 | 590.88 | 608.80 | 612.54 | |
| P/L Before Other Inc. , Int., Excpt. Items & Tax | 729.74 | 532.63 | 513.28 | 435.26 | 625.01 | |
| Other Income | 160.61 | 37.98 | 33.64 | 30.14 | 28.31 | |
| P/L Before Int., Excpt. Items & Tax | 890.35 | 570.61 | 546.92 | 465.40 | 653.32 | |
| Interest | 17.46 | 21.31 | 24.86 | 31.95 | 34.84 | |
| P/L Before Exceptional Items & Tax | 872.89 | 549.30 | 522.06 | 433.45 | 618.48 | |
| Exceptional Items | -- | -- | -- | -- | -- | |
| P/L Before Tax | 872.89 | 549.30 | 522.06 | 433.45 | 618.48 | |
| Tax | 147.85 | 130.23 | 123.93 | 102.95 | 158.34 | |
| P/L After Tax from Ordinary Activities | 725.04 | 419.07 | 398.13 | 330.50 | 460.14 | |
| Prior Year Adjustments | -- | -- | -- | -- | -- | |
| Extra Ordinary Items | -- | -- | -- | -- | -- | |
| Net Profit/(Loss) For the Period | 725.04 | 419.07 | 398.13 | 330.50 | 460.14 | |
| Equity Share Capital | 58.59 | 58.59 | 58.59 | 58.59 | 58.59 | |
| Reserves Excluding Revaluation Reserves | -- | -- | -- | -- | -- | |
| Equity Dividend Rate (%) | -- | -- | -- | -- | -- | |
| EPS Before Extra Ordinary | ||||||
| Basic EPS | 12.37 | 7.15 | 6.80 | 5.64 | 7.85 | |
| Diluted EPS | 12.37 | 7.15 | 6.80 | 5.64 | 7.85 | |
| EPS After Extra Ordinary | ||||||
| Basic EPS. | 12.37 | 7.15 | 6.80 | 5.64 | 7.85 | |
| Diluted EPS. | 12.37 | 7.15 | 6.80 | 5.64 | 7.85 | |
| Public Share Holding | ||||||
| No Of Shares (Crores) | -- | -- | -- | -- | -- | |
| Share Holding (%) | -- | -- | -- | -- | -- | |
| Promoters and Promoter Group Shareholding | ||||||
| a) Pledged/Encumbered | ||||||
| - Number of shares (Crores) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | -- | -- | |
| b) Non-encumbered | ||||||
| - Number of shares (Crores). | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total sh. of prom. and promoter group). | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total Share Cap. of the company). | -- | -- | -- | -- | -- |
11.02.2019
Analysts remain positive on Aurobindo Pharma, expect stock to return 8-30% after Q3 earnings
25.08.2018
Pharma Q1 review: Brokerages say performance a mixed bag, but are upbeat on domestic biz
10.08.2017
When Rakesh Jhunjhunwala grilled Aurobindo Pharma top brass after muted Q1 results
24.08.2016
Aurobindo to see growth in H2; capacity constraints continue: PL
